
|Articles|May 12, 2008
Irritable bowel syndrome gains new treatment
Amitiza has gained a new indication-to treat irritable bowel syndrome with constipation in women.
Advertisement
Amitiza (lubiprostone), formerly approved to treat chronic idiopathic constipation, has gained clearance for a new indication. The drug can now be used to treat irritable bowel syndrome with constipation (IBS-C) in adult women. According to Sucampo Pharmaceuticals and Takeda Pharmaceuticals America, the product is the only approved treatment for IBS-C in this country.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Executive Order Calls for Realignment of Childhood Vaccines
2
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Q&A: Pharmacists Can Address ADA Standards Across All Settings
5





























































